What comprehensive information should I know about menopause, including lifestyle measures, hormone therapy options, non‑hormonal treatments, bone health, and monitoring?

Comprehensive Guide to Menopause Management

Menopause should be diagnosed clinically based on 12 consecutive months without menstruation in women aged 45-56, and menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms in women under age 60 or within 10 years of menopause onset, while all postmenopausal women require attention to bone health and lifestyle optimization. 1

Diagnosis

Diagnose menopause based on menstrual history—specifically, 12 consecutive months of amenorrhea without another identifiable cause 1. Laboratory testing is unnecessary in most cases. Reserve FSH and estradiol measurements for women who have undergone hysterectomy without bilateral oophorectomy or when menstrual history is unclear 1. If testing is needed, obtain replicate measures since single values are unreliable.

Vasomotor Symptoms (Hot Flashes, Night Sweats)

First-Line: Menopausal Hormone Therapy

For symptomatic women under age 60 or within 10 years of menopause, MHT is the gold standard treatment 1. The benefits exceed risks in this population when properly selected.

Before initiating MHT, screen for:

• Cardiovascular disease risk factors
• Personal or family history of breast cancer
• History of venous thromboembolism
• Prior myocardial infarction or stroke 1, 2

Formulation selection:

• Use estrogen alone in women with hysterectomy 2
• Use estrogen plus progestogen in women with intact uterus 1
• Consider transdermal routes to minimize VTE risk in higher-risk patients 3

Critical caveat: MHT is NOT indicated for prevention of coronary heart disease, breast cancer, or dementia 1. These are common misconceptions that must be explicitly addressed with patients.

Non-Hormonal Options

For women who cannot or will not use MHT:

Evidence-based alternatives:

• Cognitive behavioral therapy and clinical hypnosis significantly reduce vasomotor symptom distress and are recommended 4
• SSRIs and SNRIs provide moderate symptom relief 1
• Gabapentin can be effective for moderate-to-severe symptoms 3

Not recommended despite common use:

• Mindfulness-based interventions do not reliably reduce vasomotor symptoms (though they may improve sleep and quality of life) 4
• Phytoestrogens and botanical therapies lack consistent high-quality evidence and should not be routinely recommended 4
• Acupuncture may provide subjective improvements but evidence is inconsistent 4

Genitourinary Syndrome of Menopause

For vaginal dryness, dyspareunia, and urinary symptoms:

• Low-dose vaginal estrogen is highly effective and preferred 1
• Ospemifene (oral SERM) is an alternative 1
• Vaginal moisturizers and lubricants for those declining hormonal therapy 1

These treatments have minimal systemic absorption and can be used long-term with appropriate monitoring.

Bone Health

Risk Assessment and Monitoring

Obtain baseline DEXA scan at menopause transition to establish fracture risk 2. Use the modified FRAX tool integrating fracture history, bone density, and clinical risk factors 5.

For women on osteoporosis treatment, repeat DEXA every 1-3 years to assess response 2. Alternatively, monitor bone turnover markers (C-terminal crosslinking telopeptide for antiresorptive therapy or procollagen type 1 N-terminal propeptide for anabolic therapy) to identify poor response or nonadherence 2.

Non-Pharmacological Management

All postmenopausal women require:

• Adequate calcium intake (dietary sources preferred)
• Vitamin D sufficiency (supplement if deficient) 2
• Regular weight-bearing and resistance exercise 4
• Smoking cessation 1
• Alcohol moderation 1

Pharmacological Management

For women under 60 or within 10 years of menopause with T-scores between -1.8 and -2.5:

• Consider MHT for dual benefit of symptom relief and fracture prevention 5
• Use estrogen alone in women with hysterectomy 2

For established osteoporosis at high fracture risk:

• First-line: Bisphosphonates or denosumab 2
• Alternative: Raloxifene (SERM) 2
• For very high risk: Consider referral for bone anabolic therapy (teriparatide, abaloparatide) 5
• Calcitonin only if all other options are inappropriate or not tolerated 2

Critical distinction: The hormonal changes of menopause—particularly declining estradiol and rising FSH—are the dominant drivers of bone loss, exceeding the effects of age, BMI, and lifestyle factors 6. This underscores why early intervention during the menopausal transition is crucial.

Cardiovascular and Metabolic Health

MHT is NOT recommended for primary prevention of cardiovascular disease 1. This is a critical point of confusion that must be clarified with patients.

However, the menopausal transition is associated with shifts in cardiometabolic risk 7. Use this clinical encounter to:

• Assess and optimize blood pressure
• Screen for diabetes and metabolic syndrome
• Address lipid management
• Reinforce lifestyle measures (diet, exercise, weight management)

Neurocognitive Considerations

Distinguish transient midlife cognitive complaints from long-term neurodegenerative risk 7. Many women report subjective cognitive changes during menopause, but menopause is not established as an independent dementia risk factor in the general population 7.

MHT is NOT indicated for dementia prevention 1. This must be explicitly stated when discussing treatment options.

Individualization Framework

The "timing hypothesis" is critical: Benefits of MHT are most favorable when initiated in women under 60 or within 10 years of menopause 1, 3. Absolute risks and benefits vary by age, time since menopause, formulation, and route of administration 7.

Decision algorithm:

1. Confirm menopausal status clinically
2. Assess symptom severity and impact on quality of life
3. Screen for cardiovascular and breast cancer risk
4. Determine if patient is within the favorable window (age <60 or <10 years since menopause)
5. If favorable window and no contraindications: Offer MHT as first-line
6. If outside window or contraindications present: Offer evidence-based non-hormonal options (CBT, hypnosis, SSRIs/SNRIs)
7. Address genitourinary symptoms with low-dose vaginal estrogen regardless of systemic MHT use
8. Assess bone health with DEXA and implement appropriate prevention or treatment
9. Optimize lifestyle measures universally

Common pitfall: Avoiding MHT in appropriate candidates due to outdated fears from misinterpretation of Women's Health Initiative data. The evidence clearly supports MHT safety and efficacy in younger postmenopausal women 1, 3.

Lifestyle Measures (Universal)

All postmenopausal women should embrace:

• Regular physical activity (both aerobic and resistance training)
• Balanced diet rich in calcium and vitamin D
• Smoking cessation
• Moderate alcohol consumption
• Weight management
• Sleep hygiene optimization 1, 4

These foundational interventions support bone health, metabolic function, and overall quality of life independent of pharmacological treatment decisions.